United States Biotechnology & Medical Research

Dogwood Therapeutics Inc (DWTX)

Track

Dogwood Therapeutics Inc has recorded no insider trading activity within the last three months. The most recent transactions occurred in August 2023, when executives and insiders executed multiple buy orders. Prior to this period, historical activity consisted primarily of open-market purchases by various company insiders, with limited selling activity noted in late 2022.
Ticker: DWTX Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Dogwood Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Buy 21 Aug 2023
Value US$4,787,474.60 | Price 289.13 | Shares 65,815 (+27.0%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-08-22 2023-08-21 B Purchase
2.8
Pridgen William
Non-Executive Director
65,815 +27.0%
289.13
US$4,787,475 		65,815 +27.0% 289.13 US$4,787,475
2023-08-18 2023-08-17 B Purchase
2.1
Duncan Gregory Scott

CHIEF EXECUTIVE OFFICER

Executive Director
4,306 -38.2%
290.93
US$1,128,259 		4,306 -38.2% 290.93 US$1,128,259
2022-12-12 2022-12-08 S Sale
1.6
Whitley Richard James
Non-Executive Director
13,420 -20.3%
335.62
US$3,105,016 		13,420 -20.3% 335.62 US$3,105,016
2022-05-24 2022-05-23 B Purchase
2.1
Duncan Gregory Scott

CHIEF EXECUTIVE OFFICER

Executive Director
7,500 +30.0%
4.52
US$33,900 		7,500 +30.0% 4.52 US$33,900
2022-05-24 2022-05-23 B Purchase
1.8
Walsh Angela

SVP OF FINANCE

Officer
2,000 +200.0%
4.58
US$9,150 		2,000 +200.0% 4.58 US$9,150
2022-05-19 2022-05-18 B Purchase
1.6
Whitley Richard James
Non-Executive Director
500 +25.0%
4.53
US$2,262 		500 +25.0% 4.53 US$2,262
2022-05-19 2022-05-18 B Purchase
2.8
Pridgen William
Non-Executive Director
241 +0.7%
4.50
US$1,084 		241 +0.7% 4.50 US$1,084
2022-05-18 2022-05-17 B Purchase
2.8
Pridgen William
Non-Executive Director
13,450 +58.4%
4.38
US$58,914 		13,450 +58.4% 4.38 US$58,914
2022-03-30 2022-03-29 B Purchase
2.8
Pridgen William
Non-Executive Director
600 +2.7%
4.94
US$2,964 		600 +2.7% 4.94 US$2,964
2022-03-24 2022-03-23 B Purchase
2.8
Pridgen William
Non-Executive Director
2,197 +10.9%
5.46
US$12,002 		2,197 +10.9% 5.46 US$12,002
2022-01-28 2022-01-27 B Purchase
2.8
Pridgen William
Non-Executive Director
4,180 +28.7%
5.98
US$24,998 		4,180 +28.7% 5.98 US$24,998
2022-01-07 2022-01-07 B Purchase
1.4
De La Rosa Abel
Non-Executive Director
4,000 +inf%
5.90
US$23,584 		4,000 +inf% 5.90 US$23,584
2022-01-07 2022-01-06 B Purchase
1.6
Whitley Richard James
Non-Executive Director
1,800 +900.0%
5.72
US$10,296 		1,800 +900.0% 5.72 US$10,296
2022-01-05 2022-01-04 B Purchase
1.5
Keefer David R
Non-Executive Director
5,000 +inf%
5.80
US$28,975 		5,000 +inf% 5.80 US$28,975
2022-01-04 2022-01-04 B Purchase
3.2
Thomas John C
Non-Executive Director
1,000 +inf%
5.65
US$5,650 		1,000 +inf% 5.65 US$5,650
2022-01-04 2022-01-03 B Purchase
2.8
Pridgen William
Non-Executive Director
2,215 +18.0%
5.43
US$12,034 		2,215 +18.0% 5.43 US$12,034
2021-12-23 2021-12-23 B Purchase
1.6
Whitley Richard James
Non-Executive Director
200 +inf%
5.73
US$1,145 		200 +inf% 5.73 US$1,145
2021-12-22 2021-12-21 B Purchase
2.8
Pridgen William
Non-Executive Director
8,827 +252.2%
5.66
US$49,997 		8,827 +252.2% 5.66 US$49,997
2021-12-22 2021-12-21 B Purchase
2.1
Duncan Gregory Scott

CHIEF EXECUTIVE OFFICER

Executive Director
5,000 +25.0%
5.52
US$27,615 		5,000 +25.0% 5.52 US$27,615
2021-04-07 2021-04-06 PP Planned purchase
2.1
Duncan Gregory Scott

Chief Executive Officer

Executive Director
382 +2.0%
6.36
US$2,429 		382 +2.0% 6.36 US$2,429
2021-04-06 2021-04-05 PP Planned purchase
2.1
Duncan Gregory Scott

Chief Executive Officer

Executive Director
15,675 +401.5%
6.17
US$96,757 		15,675 +401.5% 6.17 US$96,757
2021-02-01 2021-01-29 B Purchase
2.8
Pridgen William
Non-Executive Director
3,500 +inf%
7.47
US$26,145 		3,500 +inf% 7.47 US$26,145
2021-02-01 2021-01-28 B Purchase
1.8
Walsh Angela

VP of Finance

Officer
1,000 +inf%
7.30
US$7,300 		1,000 +inf% 7.30 US$7,300
2020-12-21 2020-12-17 B Purchase
2.8
Pridgen William
Non-Executive Director
1,500 +0.2%
11.98
US$17,970 		1,500 +0.2% 11.98 US$17,970
Explore more

More insider trading research around Dogwood Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America